Stay updated on IBI310 Combo vs Sorafenib in HCC Clinical Trial
Sign up to get notified when there's something new on the IBI310 Combo vs Sorafenib in HCC Clinical Trial page.

Latest updates to the IBI310 Combo vs Sorafenib in HCC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check31 days agoNo Change Detected
- Check38 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference5%
- Check45 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
- Check60 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.3%
- Check67 days agoChange DetectedThe intervention type has been updated to 'Verified 2022-09 by Innovent Biologics (Suzhou) Co. Ltd.' with the last known status as 'Recruiting', reflecting a revision from v2.13.3 to v2.14.0.SummaryDifference3%
- Check96 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.3%
Stay in the know with updates to IBI310 Combo vs Sorafenib in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IBI310 Combo vs Sorafenib in HCC Clinical Trial page.